Generic name · Chemotherapy / HER2 Biologic
Trastuzumab J-Code / HCPCS Code
In short
Trastuzumab is billed under HCPCS J9355 — Injection, trastuzumab, excludes biosimilar, 10 mg. One billing unit is 10 mg.
Trastuzumab biosimilars and trastuzumab with hyaluronidase have their own HCPCS codes.
Reference
- Code
- J9355 — Injection, trastuzumab, excludes biosimilar, 10 mgMed-Code curated
- Billing unit
- 10 mg
- Same code in the directory
- Herceptin
- Pharmacologic class
- HER2/neu Receptor Antagonist; EndoglycosidaseFrom the FDA listings below
- Labelers
- Accord BioPharma Inc.; Amgen, Inc; Biocon Biologics Inc.; Cephalon, Inc.; Daiichi Sankyo Inc.; Genentech, Inc.; Mylan Institutional LLC; Organon LLCand 1 more
- J-code category
- Chemotherapy / HER2 Biologic
FDA-listed products
Finished products whose name and route match this directory entry.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Herceptintrastuzumab | Trastuzumab 150 mg/7.4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Genentech, Inc. | 50242-132 |
| Herzumatrastuzumab | Trastuzumab 150 mg/7.15mL | Injection, Powder, Lyophilized, For solutionIntravenous | Cephalon, Inc. | 63459-303 |
| Kanjintitrastuzumab-anns | Trastuzumab 420 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Amgen, Inc | 55513-132 |
| Kanjintitrastuzumab-anns | Trastuzumab 150 mg/7.15mL | Injection, Powder, Lyophilized, For solutionIntravenous | Amgen, Inc | 55513-141 |
| Ogivritrastuzumab | Trastuzumab 150 mg/7.4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Mylan Institutional LLC | 67457-991 |
| Ogivritrastuzumab-dkst | Trastuzumab 150 mg/7.4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Biocon Biologics Inc. | 83257-001 |
| Ogivritrastuzumab-dkst | Trastuzumab 420 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Biocon Biologics Inc. | 83257-003 |
| Ontruzanttrastuzumab | Trastuzumab 150 mg/1 | Injection, Powder, Lyophilized, For solutionIntravenous | Organon LLC | 78206-147 |
| Trazimeratrastuzumab-qyyp | Trastuzumab 150 mg/7.15mL | Injection, Powder, Lyophilized, For solutionIntravenous | Pfizer Laboratories Div Pfizer Inc | 0069-0308 |
Other products with this name
Same name but a different route, formulation or combination — the code above does not apply to these.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Enhertufam-trastuzumab deruxtecan-nxki | Trastuzumab deruxtecan 100 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | Daiichi Sankyo Inc. | 65597-406 |
| Herceptin Hylectatrastuzumab and hyaluronidase-oysk | Trastuzumab 600 mg/5mL; Hyaluronidase (Human recombinant) 10000 U/5mL | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-077 |
| Hercessitrastuzumab-strf | Trastuzumab-strf 150 mg/7.4mL | Injection, Powder, Lyophilized, For solutionIntravenous | Accord BioPharma Inc. | 69448-015 |
| Hercessitrastuzumab-strf | Trastuzumab-strf 420 mg/20mL | Injection, Powder, Lyophilized, For solutionIntravenous | Accord BioPharma Inc. | 69448-016 |
| Hercessitrastuzumab-strf | — | Kit | Accord BioPharma Inc. | 69448-035 |
| Herzumatrastuzumab | — | Kit | Cephalon, Inc. | 63459-305 |
| Kadcylaado-trastuzumab emtansine | Trastuzumab emtansine 20 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | Genentech, Inc. | 50242-087 |
| Kadcylaado-trastuzumab emtansine | Trastuzumab emtansine 20 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | Genentech, Inc. | 50242-088 |
| Ogivritrastuzumab | — | Kit | Mylan Institutional LLC | 67457-847 |
| Ogivritrastuzumab-dkst | — | Kit | Biocon Biologics Inc. | 83257-004 |
| Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf | Pertuzumab 1200 mg/15mL + 2 more ingredients | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-245 |
| Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf | Pertuzumab 600 mg/10mL + 2 more ingredients | Injection, SolutionSubcutaneous | Genentech, Inc. | 50242-260 |
| Trazimeratrastuzumab-qyyp | — | Kit | Pfizer Laboratories Div Pfizer Inc | 0069-0305 |
NDCs billed under J9355
CMS’s ASP NDC–HCPCS crosswalk (effective October 1, 2026 through December 31, 2026) assigns 1 NDC to J9355 for Herceptin. Billing units per package are CMS’s figures for this code’s unit.
| Drug | NDC (11-digit) | Labeler | Package | Billing units per package |
|---|---|---|---|---|
| Herceptin | 50242-0132-01 | Genentech, Inc. | 1 | 15 |